These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 19513106)

  • 1. In global health research, is it legitimate to stop clinical trials early on account of their opportunity costs?
    Lavery JV; Singer PA; Ridzon R; Singh JA; Slutsky AS; Anisko JJ; Buchanan D
    PLoS Med; 2009 Jun; 6(6):e1000071. PubMed ID: 19513106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A developing country response to Lavery et al. "In global health research, is it legitimate to stop clinical trials early on account of their opportunity costs?".
    Wassenaar DR; Ramjee G
    BMC Med Ethics; 2009 Sep; 10():16. PubMed ID: 19788765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microbicide research in developing countries: have we given the ethical concerns due consideration?
    Moodley K
    BMC Med Ethics; 2007 Sep; 8():10. PubMed ID: 17877834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microbicide research: current and future directions.
    Ramjee G
    Curr Opin HIV AIDS; 2010 Jul; 5(4):316-21. PubMed ID: 20543607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical development of microbicides for the prevention of HIV infection.
    D'Cruz OJ; Uckun FM
    Curr Pharm Des; 2004; 10(3):315-36. PubMed ID: 14754390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Women design their own vaginal microbicide trial: Suggestions on how to improve adherence from former participants of HIV prevention trials.
    Miller L; Morar N; Kapiga S; Ramjee G; Hayes R
    PLoS One; 2021; 16(1):e0244652. PubMed ID: 33411782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "We have our protector": misperceptions of protection against HIV among participants in a microbicide efficacy trial.
    Mantell JE; Morar NS; Myer L; Ramjee G
    Am J Public Health; 2006 Jun; 96(6):1073-7. PubMed ID: 16670239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrating behavioral and social science research into microbicide clinical trials: challenges and opportunities.
    Tolley EE; Severy LJ
    Am J Public Health; 2006 Jan; 96(1):79-83. PubMed ID: 16317214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trials and tribulations of coronavirus disease-2019 research: with a few bright lights in the fog.
    Di Pasquale G; Maggioni AP; Gervasoni C; Andreotti F
    J Cardiovasc Med (Hagerstown); 2020 Nov; 21(11):841-844. PubMed ID: 32858645
    [No Abstract]   [Full Text] [Related]  

  • 10. Engaging male partners in women's microbicide use: evidence from clinical trials and implications for future research and microbicide introduction.
    Lanham M; Wilcher R; Montgomery ET; Pool R; Schuler S; Lenzi R; Friedland B
    J Int AIDS Soc; 2014; 17(3 Suppl 2):19159. PubMed ID: 25224618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Learning from the private sector: towards a keener understanding of the end-user for microbicide introduction planning.
    Lin AH; Breger TL; Barnhart M; Kim A; Vangsgaard C; Harris E
    J Int AIDS Soc; 2014; 17(3 Suppl 2):19162. PubMed ID: 25224619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 'HIV has a woman's face': vaginal microbicides and a case of ambiguous failure.
    Montgomery CM
    Anthropol Med; 2015 Dec; 22(3):250-62. PubMed ID: 26440223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How some patients in new-drug trials can get cut off.
    Anand G
    Wall St J (East Ed); 2003 Dec; ():A1, A11. PubMed ID: 14971381
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis.
    Suman VJ; Dueck A; Sargent DJ
    Cancer Invest; 2008 Jun; 26(5):439-44. PubMed ID: 18568764
    [No Abstract]   [Full Text] [Related]  

  • 15. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Twice-daily application of HIV microbicides alter the vaginal microbiota.
    Ravel J; Gajer P; Fu L; Mauck CK; Koenig SS; Sakamoto J; Motsinger-Reif AA; Doncel GF; Zeichner SL
    mBio; 2012 Dec; 3(6):. PubMed ID: 23249810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. General issues and precautions in the design for clinical trials of investigational new drugs.
    Hu LP; Bao XL
    Zhong Xi Yi Jie He Xue Bao; 2011 Feb; 9(2):138-42. PubMed ID: 21288447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges in microbicide trial design and implementation.
    van de Wijgert J; Jones H
    Stud Fam Plann; 2006 Jun; 37(2):123-9. PubMed ID: 16832986
    [No Abstract]   [Full Text] [Related]  

  • 19. Topical microbicides for prevention of sexually transmitted infections.
    Obiero J; Mwethera PG; Wiysonge CS
    Cochrane Database Syst Rev; 2012 Jun; (6):CD007961. PubMed ID: 22696373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Scientific and ethical considerations in trial design for investigational agents for the treatment of human immunodeficiency virus infection.
    Feinberg J; Japour AJ
    Clin Infect Dis; 2003 Jan; 36(2):201-6. PubMed ID: 12522753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.